Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
1.370
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
November 03, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
A Preview Of Editas Medicine's Earnings
November 02, 2023
Via
Benzinga
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
November 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Analyst Ratings for Editas Medicine
October 18, 2023
Via
Benzinga
Is Editas Stock a Buy Now?
October 07, 2023
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
Expert Ratings for Editas Medicine
September 29, 2023
Via
Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
October 18, 2023
Both are in a race against time to commercialize a medicine before cash runs out.
Via
The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
September 29, 2023
Via
Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 17, 2023
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
Via
InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
October 17, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
October 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
October 05, 2023
It's key to understand the resources it will take to deliver a company's pipeline.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
September 29, 2023
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market...
Via
Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.